Still, the BAR‐body concept may be a powerful tool as an additional future treatment option for B‐cell lymphomas considering that several B‐cell lymphoma autoantigens have already been identified, including LRPAP1, neurabin‐I/SAMD14, and Ars2. This evidence concerns the gene LRPAP1 and B-cell non-Hodgkin lymphoma.